Gland Pharma Jumped 3.24% to ₹2,989.70 After Brokerage Call Update — Levels, Volumes and the Follow-Up to Track

Gland Pharma share price today, and the reason behind it

Shares of Gland Pharma last changed hands at ₹2,989.70 on the NSE board at the close of the last trading session on Tuesday, 29 September 2026 — +93.70 or +3.24% from the previous close of ₹2,896.00. Behind the number, the move is large enough to stand out from the index, so it is being driven by something specific to the company rather than by market beta.

The market is closed at the time of writing (Tuesday, 09:05 pm IST); the levels below are the close of the Tuesday, 29 September 2026 session.

What you need to know

• Where it trades: Gland Pharma is at ₹2,989.70, +93.70 (+3.24%) versus the previous close of ₹2,896.00.
• Why it is moving: a brokerage-call story — one business desk filed on the company in the last few hours.
• Today's band: ₹2,896.60 to ₹3,024.00, against an open of ₹2,896.60 — the stock is defending its opening print.
• Twelve-month context: 1.72% below the ₹3,042 high and 89.99% above the ₹1,574 low, so the stock sits in the upper part of its own range.
• Participation: turnover is running at 1.5x the twenty-day average, which is ordinary flow — the move lacks a volume endorsement so far.
• What to watch: whether volume confirms the call — a rating change that moves price without turnover is usually just a headline, not a repositioning.

The brokerage call angle

The reason Gland Pharma is on the desks today is a brokerage call story — reported by one desk so far, with the headlines linked below. A published target is one desk's discounted cash-flow view, not a forecast of the next session; the useful information is the change in assumptions behind the call, not the number itself.

Where the price stands right now

Who is reporting what

Headlines are listed for context and link straight to the publisher. The prices, ranges and tables on this page are read independently from exchange data at the timestamp shown.

• Top 5 Sumeet Bagadia's breakout stocks: Gland Pharma, Astra Micro, Meesho, Westlife, Ujjivan | Target price, stop-loss — Livemint

How much a target price is really worth

A brokerage target is the output of one desk's model over a twelve-month horizon, not a forecast of the next session. The number itself is the least useful part of the note; what matters is which assumption changed — volume growth, realisation, margin, capex, or the multiple applied to the terminal year. A target raised purely by rolling the valuation year forward carries no new information at all.

The second filter is confirmation. A rating change that moves the price without a matching rise in turnover is a headline being traded by small hands. A rating change accompanied by turnover well above the stock's own average means institutions are actually repositioning, and those moves persist.

Gland Pharma is at ₹2,989.70 today, inside a twelve-month band of ₹1,574 to ₹3,042. Any published target should be read against that band: a target inside the range the stock has already traded in is a valuation view, one far above it is a change in thesis.

Trailing returns in context

What the returns table is saying

Over the last week Gland Pharma has gained +1.68% and over the month +4.04%. Both horizons pointing the same way means the recent move is an extension of the existing trend rather than a reversal.

The twelve-month return of +49.63% is the context long-term holders judge the stock on. A moderate one-year move means the stock has broadly tracked its earnings path rather than being re-rated in either direction.

Reading the price against its own ranges

Over the last twelve months the price has covered ₹1,574 to ₹3,042. The current level is 96% of the way through that band, 1.72% below the 52-week high and 89.99% above the 52-week low. Trading this close to the yearly high means there is little overhead supply from earlier buyers, which is why breakouts here tend to extend — but it also leaves no cushion if the news flow turns.

Traded quantity of 8,76,878 shares is 1.45x the 20-day average of 6,03,412. Turnover close to the recent norm suggests an orderly session rather than a scramble, so the move reflects ordinary two-way flow.

Price action, level by level

Gland Pharma has traded between ₹2,896.60 and ₹3,024.00 in this session against an open of ₹2,896.60 and a previous close of ₹2,896.00. That is a band of ₹127.40, or 4.26% of the current price — a wide day, which means intraday positions are being forced rather than chosen.

Holding above the open at ₹2,896.60 matters because it is the level intraday desks use as the session pivot: buyers who entered at the open are in profit, so there is no forced supply from that cohort.

In market-structure terms this is a repricing session rather than a drift session, and repricing sessions are confirmed or rejected by the next day's low, not by the close.

The follow-up checklist

For this brokerage call story specifically, watch whether volume confirms the call — a rating change that moves price without turnover is usually just a headline, not a repositioning. On the chart, the ₹3,024.00 high and ₹2,896.60 low of the last session are the reference levels — a higher low in the next session turns a headline reaction into a trend, a break of that low usually voids it. Participation is the third check: the move needs turnover at or above the stock's own 20-day average of 6,03,412 shares to be read as positioning rather than a squeeze.

What this means for investors

For a trader, the immediate question is not direction but whether the repricing holds. ₹3,024.00 and ₹2,896.60 are the day's markers; the next session's ability to keep the move inside that band — a higher low after an up-move, a lower high after a fall — is what separates a trend from a one-day event.

For a long-term shareholder, one session tells you very little. The stock is 1.72% off its twelve-month high, so the more useful exercise is comparing that drawdown with the change in earnings over the same period: price falling faster than profits is an opportunity, the reverse is a warning.

On risk: this report is a reading of live exchange data at a point in time, and intraday levels change. Position sizing — not conviction about the story — is what determines the outcome of a trade built on a headline, and averaging into a falling price without a change in the underlying facts is how a trade becomes an unintended long-term holding.

The bottom line

Gland Pharma is being bought on a brokerage-call story, and at ₹2,989.70 the move is not yet backed by turnover above its own average, which is the version of a rally that tends to fade. The day's ₹2,896.60–₹3,024.00 band is the frame for the next session, and whether volume confirms the call — a rating change that moves price without turnover is usually just a headline, not a repositioning is what resolves the story either way.

Where to track GLAND next

Live price, charts and technicals stay on the Gland Pharma stock page, and every filed quarter is tabulated on its quarterly results page. Both pages refresh from the exchange feed through the session, so they carry a later reading than this report once the market has moved on.

Frequently asked questions

What is the Gland Pharma share price today?

Gland Pharma (GLAND) last traded at ₹2,989.70, +93.70 (+3.24%) against the previous close of ₹2,896.00, read from the NSE board at the close of the last trading session on Tuesday, 29 September 2026.

Why is Gland Pharma in the news today?

1 business publisher ran headlines on the company in the last session — a brokerage call story. Their reports are linked above; the levels and tables here are read independently from exchange data.

What is the 52-week high and low of GLAND?

Over the last twelve months GLAND has traded between a low of ₹1,574 and a high of ₹3,042, computed from the adjusted daily series.

Is GLAND up or down today?

GLAND gained +3.24% in the last session, trading between ₹2,896.60 and ₹3,024.00 against an open of ₹2,896.60.

Is the market open right now?

No. The market is closed at the time of writing (Tuesday, 09:05 pm IST); the levels below are the close of the Tuesday, 29 September 2026 session.

Key takeaways

• Last price: ₹2,989.70 (+3.24%) — higher at the time of writing
• Day range: ₹2,896.60 – ₹3,024.00
• 52-week high: ₹3,042

About this report

Every figure on this page is read from a primary source at the timestamp shown — exchange boards for equities and indices, the exchange bid book for IPOs, published association rates for bullion, and consolidated exchange quotes for crypto — with no estimation or third-party commentary. Historical fields such as trailing returns and 52-week extremes are computed on the adjusted daily series so splits and bonuses do not create false gaps. A timestamp outside market hours reflects the last traded or last published value, not a live tick.

Related live pages

• Gland Pharma share price
• Gland Pharma quarterly results
• Stocks in news
• Top gainers
• Market dashboard

Sources

• NSE live board data via our exchange data feed
• Headline attribution links above point to the original publishers
• TrendRipperX Gland Pharma stock page

“This report is generated automatically from live exchange and official association data at the time stamped above. Prices move continuously — verify on the source before acting. Nothing here is investment advice.”